8-K Announcements
6Material company update
Feb 25, 2026·SEC
Material company update
Feb 18, 2026·SEC
Material company update
Feb 18, 2026·SEC
Charles River Laboratories International, Inc.(CRL)Earnings, Financials & Key Ratios
CRL•NYSE
$181.73
$8.97B mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryContract Research and Preclinical Services
AboutCharles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.Show more
- Revenue$4.02B-0.9%
- EBITDA$911M+54.7%
- Net Income-$144M-1501.7%
- EPS (Diluted)-2.91-1555.0%
- Gross Margin30.52%-7.2%
- EBITDA Margin22.69%+56.0%
- Operating Margin12.65%+125.3%
- Net Margin-3.59%-1514.1%
- ROE-4.3%-1595.4%
- ROIC6.3%+130.5%
- Debt/Equity0.95+22.9%
- Interest Coverage4.74+173.1%
CRL Key Insights
Charles River Laboratories International, Inc. (CRL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 4.0% through buybacks
✗Weaknesses
- ✗Weak 3Y average ROE of 3.4%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRL Price & Volume
Charles River Laboratories International, Inc. (CRL) stock price & volume — 10-year historical chart
Loading chart...
CRL Growth Metrics
Charles River Laboratories International, Inc. (CRL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.41%
5 Years6.55%
3 Years0.33%
TTM-0.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1501.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2073.33%
Return on Capital
10 Years9.7%
5 Years8.39%
3 Years6.82%
Last Year8.09%
CRL Recent Earnings
Charles River Laboratories International, Inc. (CRL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 12/12 qtrs (100%)
Q1 2026Latest
Feb 18, 2026EPS
$2.39
Est $2.33
+2.6%
Revenue
$994M
Est $987M
+0.7%
Q4 2025
Nov 5, 2025EPS
$2.43
Est $2.32
+4.7%
Revenue
$1.0B
Est $987M
+1.8%
Q3 2025
Aug 6, 2025EPS
$3.12
Est $2.50
+24.8%
Revenue
$1.0B
Est $969M
+6.5%
Q2 2025
May 7, 2025EPS
$2.34
Est $2.06
+13.6%
Revenue
$984M
Est $959M
+2.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 18, 2026 | $2.39vs $2.33+2.6% | $994Mvs $987M+0.7% |
| Q4 2025 | Nov 5, 2025 | $2.43vs $2.32+4.7% | $1.0Bvs $987M+1.8% |
| Q3 2025 | Aug 6, 2025 | $3.12vs $2.50+24.8% | $1.0Bvs $969M+6.5% |
| Q2 2025 | May 7, 2025 | $2.34vs $2.06+13.6% | $984Mvs $959M+2.6% |
Based on last 12 quarters of dataView full earnings history →
CRL Peer Comparison
Charles River Laboratories International, Inc. (CRL) competitors in Contract Research and Preclinical Services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IQV | 29.95B | 176.47 | 22.51 | 5.87% | 8.33% | 22.11% | 2.44 | |
 MEDP | 12.19B | 426.79 | 27.93 | 19.97% | 17.19% | 120.89% | 0.55 | |
 ICLR | 9.48B | 124.13 | 13.03 | 1.99% | 7.4% | 6.32% | 0.38 | |
 PRA | 1.27B | 24.60 | 24.85 | -2.67% | 6.04% | 4.95% | 0.32 | |
 LBRT | 5.26B | 32.47 | 36.48 | -7.16% | 3.71% | 7.39% | 0.42 | |
 LH | 21.14B | 256.93 | 24.56 | 7.25% | 6.66% | 10.89% | 0.83 | |
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 |
Compare CRL vs Peers
Charles River Laboratories International, Inc. (CRL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRL Income Statement
Charles River Laboratories International, Inc. (CRL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.86B | 2.27B | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B |
| Revenue Growth % | 10.48% | 21.99% | 15.67% | 11.55% | 21.08% | 12.31% | 3.86% | -1.92% | -0.85% |
| Cost of Goods Sold | 1.16B | 1.43B | 1.66B | 1.85B | 2.21B | 2.51B | 2.63B | 2.72B | 2.79B |
| COGS % of Revenue | 62.27% | 62.93% | 63.44% | 63.28% | 62.3% | 63.21% | 63.61% | 67.12% | 69.48% |
| Gross Profit | 700.92M▲ 0% | 840.07M▲ 19.9% | 958.31M▲ 14.1% | 1.07B▲ 12.0% | 1.33B▲ 24.3% | 1.46B▲ 9.6% | 1.5B▲ 2.7% | 1.33B▼ 11.4% | 1.23B▼ 8.0% |
| Gross Margin % | 37.73% | 37.07% | 36.56% | 36.72% | 37.7% | 36.79% | 36.39% | 32.88% | 30.52% |
| Gross Profit Growth % | 8.85% | 19.85% | 14.08% | 12.02% | 24.32% | 9.59% | 2.73% | -11.36% | -7.98% |
| Operating Expenses | 412.64M | 508.68M | 607.16M | 640.81M | 744.78M | 811.68M | 885.29M | 1.1B | 717.73M |
| OpEx % of Revenue | 22.21% | 22.45% | 23.16% | 21.92% | 21.04% | 20.41% | 21.44% | 27.27% | 17.87% |
| Selling, General & Admin | 371.27M | 443.85M | 517.62M | 528.93M | 619.92M | 665.1M | 747.86M | 751M | 743.07M |
| SG&A % of Revenue | 19.99% | 19.59% | 19.75% | 18.09% | 17.51% | 16.73% | 18.11% | 18.54% | 18.51% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 41.37M | 64.83M | 89.54M | 111.88M | 124.86M | 146.58M | 137.44M | 353.47M | -25.34M |
| Operating Income | 288.28M▲ 0% | 331.38M▲ 15.0% | 351.15M▲ 6.0% | 432.73M▲ 23.2% | 589.86M▲ 36.3% | 650.98M▲ 10.4% | 617.26M▼ 5.2% | 227.35M▼ 63.2% | 507.84M▲ 123.4% |
| Operating Margin % | 15.52% | 14.62% | 13.4% | 14.8% | 16.66% | 16.37% | 14.95% | 5.61% | 12.65% |
| Operating Income Growth % | 21.36% | 14.95% | 5.97% | 23.23% | 36.31% | 10.36% | -5.18% | -63.17% | 123.38% |
| EBITDA | 419.44M | 493.16M | 549.25M | 667.65M | 855.4M | 954.85M | 931.38M | 589.09M | 911.15M |
| EBITDA Margin % | 22.58% | 21.76% | 20.95% | 22.83% | 24.16% | 24.01% | 22.55% | 14.55% | 22.69% |
| EBITDA Growth % | 15.16% | 17.58% | 11.37% | 21.56% | 28.12% | 11.63% | -2.46% | -36.75% | 54.67% |
| D&A (Non-Cash Add-back) | 131.16M | 161.78M | 198.09M | 234.92M | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| EBIT | 326.73M | 345.45M | 364.97M | 533.55M | 554.62M | 682.28M | 717.99M | 219.4M | 507.84M |
| Net Interest Income | -29.09M | -62.96M | -59.36M | -85.6M | -73.26M | -58.51M | -131.51M | -117.71M | -102.09M |
| Interest Income | 690K | 812K | 1.52M | 834K | 652K | 780K | 5.2M | 8.57M | 4.94M |
| Interest Expense | 29.78M | 63.77M | 60.88M | 86.43M | 73.91M | 59.29M | 136.71M | 126.29M | 107.03M |
| Other Income/Expense | 8.67M | -49.7M | -47.07M | 14.38M | -109.15M | -27.99M | -35.98M | -134.23M | -607.34M |
| Pretax Income | 296.95M▲ 0% | 281.68M▼ 5.1% | 304.08M▲ 8.0% | 447.11M▲ 47.0% | 480.71M▲ 7.5% | 622.99M▲ 29.6% | 581.28M▼ 6.7% | 93.11M▼ 84.0% | -99.5M▼ 206.9% |
| Pretax Margin % | 15.99% | 12.43% | 11.6% | 15.29% | 13.58% | 15.67% | 14.08% | 2.3% | -2.48% |
| Income Tax | 171.37M | 54.46M | 50.02M | 81.81M | 81.87M | 130.38M | 100.91M | 67.82M | 42.66M |
| Effective Tax Rate % | 57.71% | 19.33% | 16.45% | 18.3% | 17.03% | 20.93% | 17.36% | 72.84% | -42.87% |
| Net Income | 123.36M▲ 0% | 226.37M▲ 83.5% | 252.02M▲ 11.3% | 364.3M▲ 44.6% | 390.98M▲ 7.3% | 486.23M▲ 24.4% | 474.62M▼ 2.4% | 10.3M▼ 97.8% | -144.34M▼ 1501.7% |
| Net Margin % | 6.64% | 9.99% | 9.61% | 12.46% | 11.04% | 12.23% | 11.49% | 0.25% | -3.59% |
| Net Income Growth % | -20.3% | 83.51% | 11.33% | 44.55% | 7.32% | 24.36% | -2.39% | -97.83% | -1501.75% |
| Net Income (Continuing) | 125.59M | 227.22M | 254.06M | 365.31M | 398.84M | 492.61M | 480.37M | 25.29M | -142.16M |
| Discontinued Operations | 0 | 1.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 18.94M | 20.97M | 31.89M | 29.07M | 57.17M | 47.21M | 62.12M | 46.58M | 46.56M |
| EPS (Diluted) | 2.54▲ 0% | 4.62▲ 81.9% | 5.07▲ 9.7% | 7.20▲ 42.0% | 7.60▲ 5.6% | 9.48▲ 24.7% | 9.22▼ 2.7% | 0.20▼ 97.8% | -2.91▼ 1555.0% |
| EPS Growth % | -21.36% | 81.89% | 9.74% | 42.01% | 5.56% | 24.74% | -2.74% | -97.83% | -1555% |
| EPS (Basic) | 2.60 | 4.72 | 5.17 | 7.35 | 7.77 | 9.57 | 9.27 | 0.20 | -2.91 |
| Diluted Shares Outstanding | 48.56M | 49.02M | 49.69M | 50.61M | 51.42M | 51.3M | 51.45M | 51.63M | 49.56M |
| Basic Shares Outstanding | 47.48M | 47.95M | 48.73M | 49.55M | 50.29M | 50.81M | 51.23M | 51.38M | 49.56M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CRL Balance Sheet
Charles River Laboratories International, Inc. (CRL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 826.63M | 897.84M | 1.02B | 1.2B | 1.27B | 1.44B | 1.61B | 1.4B | 1.45B |
| Cash & Short-Term Investments | 163.79M | 195.44M | 238.96M | 229.45M | 246.3M | 233.91M | 276.77M | 194.61M | 213.77M |
| Cash Only | 163.79M | 195.44M | 238.01M | 228.42M | 245.24M | 233.91M | 276.77M | 194.61M | 213.77M |
| Short-Term Investments | 0 | 0 | 941K | 1.02M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 430.02M | 472.25M | 514.03M | 617.74M | 650.38M | 752.39M | 780.38M | 720.91M | 708.86M |
| Days Sales Outstanding | 84.49 | 76.06 | 71.58 | 77.11 | 67.06 | 69.07 | 68.98 | 64.97 | 64.44 |
| Inventory | 114.96M | 127.89M | 160.66M | 185.69M | 199.15M | 255.81M | 380.26M | 278.54M | 299.1M |
| Days Inventory Outstanding | 36.28 | 32.73 | 35.26 | 36.63 | 32.96 | 37.15 | 52.84 | 37.4 | 39.13 |
| Other Current Assets | 0 | 300K | 731K | 3.07M | 0 | 107.58M | 83.38M | 105.8M | 8.65M |
| Total Non-Current Assets | 2.1B | 2.96B | 3.67B | 4.29B | 5.75B | 6.16B | 6.59B | 6.13B | 5.69B |
| Property, Plant & Equipment | 781.97M | 932.88M | 1.18B | 1.3B | 1.58B | 1.86B | 2.03B | 2.02B | 2.02B |
| Fixed Asset Turnover | 2.38x | 2.43x | 2.21x | 2.24x | 2.23x | 2.14x | 2.03x | 2.01x | 1.99x |
| Goodwill | 804.91M | 1.25B | 1.54B | 1.81B | 2.71B | 2.85B | 3.1B | 2.85B | 2.76B |
| Intangible Assets | 369.76M | 610.89M | 689.41M | 787.6M | 1.06B | 955.27M | 864.05M | 723.4M | 340M |
| Long-Term Investments | 71.1M | 88.59M | 122.98M | 221.8M | 201.35M | 311.6M | 243.81M | 218.35M | 206.97M |
| Other Non-Current Assets | 52.9M | 55.17M | 89.64M | 130.82M | 151.54M | 148.28M | 309.38M | 278.23M | 293.19M |
| Total Assets | 2.93B▲ 0% | 3.86B▲ 31.6% | 4.69B▲ 21.7% | 5.49B▲ 17.0% | 7.02B▲ 27.9% | 7.6B▲ 8.2% | 8.2B▲ 7.8% | 7.53B▼ 8.1% | 7.14B▼ 5.2% |
| Asset Turnover | 0.63x | 0.59x | 0.56x | 0.53x | 0.50x | 0.52x | 0.50x | 0.54x | 0.56x |
| Asset Growth % | 8.04% | 31.6% | 21.7% | 17.01% | 27.93% | 8.24% | 7.79% | -8.13% | -5.22% |
| Total Current Liabilities | 463.5M | 558.22M | 710.18M | 839.75M | 1.03B | 1.09B | 1.06B | 994.1M | 1.12B |
| Accounts Payable | 77.84M | 66.25M | 111.5M | 122.47M | 198.13M | 205.91M | 168.94M | 140.34M | 148.8M |
| Days Payables Outstanding | 24.56 | 16.96 | 24.47 | 24.16 | 32.79 | 29.9 | 23.47 | 18.84 | 19.47 |
| Short-Term Debt | 31M | 31.42M | 35.55M | 47.2M | 101K | 0 | 0 | 0 | 61.06M |
| Deferred Revenue (Current) | 117.57M | 145.14M | 204.88M | 250.19M | 219.7M | 264.26M | 241.82M | 248.32M | 210.42M |
| Other Current Liabilities | 92.81M | 181.18M | 169.71M | 217.5M | 307.01M | 401.65M | 431.04M | 373.43M | 392.19M |
| Current Ratio | 1.78x | 1.61x | 1.44x | 1.43x | 1.23x | 1.32x | 1.52x | 1.41x | 1.29x |
| Quick Ratio | 1.54x | 1.38x | 1.21x | 1.21x | 1.04x | 1.08x | 1.16x | 1.13x | 1.02x |
| Cash Conversion Cycle | 96.21 | 91.84 | 82.37 | 89.58 | 67.22 | 76.31 | 98.34 | 83.53 | 84.1 |
| Total Non-Current Liabilities | 1.4B | 1.96B | 2.32B | 2.51B | 3.4B | 3.49B | 3.48B | 3.03B | 2.8B |
| Long-Term Debt | 1.11B | 1.64B | 1.82B | 1.9B | 2.92B | 2.71B | 2.65B | 2.24B | 2.55B |
| Capital Lease Obligations | 27.88M | 26.05M | 143.78M | 184.64M | 252.97M | 389.75M | 419.23M | 483.79M | 458.7M |
| Deferred Tax Liabilities | 89.54M | 143.63M | 167.28M | 217.03M | 239.72M | 215.58M | 191.35M | 106.96M | 95.2M |
| Other Non-Current Liabilities | 166.93M | 118.65M | 161.95M | 185.74M | -30.69M | 174.82M | 223.19M | 195.21M | -341.38M |
| Total Liabilities | 1.87B | 2.52B | 3.03B | 3.35B | 4.43B | 4.58B | 4.54B | 4.02B | 3.92B |
| Total Debt | 1.15B | 1.7B | 2.02B | 2.16B | 3.21B | 3.1B | 3.07B | 2.72B | 3.07B |
| Net Debt | 981.31M | 1.5B | 1.79B | 1.93B | 2.96B | 2.86B | 2.79B | 2.53B | 2.85B |
| Debt / Equity | 1.08x | 1.27x | 1.22x | 1.01x | 1.24x | 1.02x | 0.84x | 0.78x | 0.95x |
| Debt / EBITDA | 2.73x | 3.44x | 3.69x | 3.24x | 3.75x | 3.24x | 3.29x | 4.62x | 3.36x |
| Net Debt / EBITDA | 2.34x | 3.05x | 3.25x | 2.89x | 3.47x | 3.00x | 3.00x | 4.29x | 3.13x |
| Interest Coverage | 10.97x | 5.42x | 5.99x | 6.17x | 7.50x | 11.51x | 5.25x | 1.74x | 4.74x |
| Total Equity | 1.06B▲ 0% | 1.34B▲ 25.8% | 1.67B▲ 24.5% | 2.14B▲ 28.6% | 2.59B▲ 20.9% | 3.02B▲ 16.6% | 3.66B▲ 21.0% | 3.51B▼ 4.1% | 3.21B▼ 8.5% |
| Equity Growth % | 24.62% | 25.78% | 24.52% | 28.63% | 20.91% | 16.65% | 21.02% | -4.12% | -8.46% |
| Book Value per Share | 21.91 | 27.30 | 33.54 | 42.36 | 50.40 | 58.94 | 71.12 | 67.95 | 64.79 |
| Total Shareholders' Equity | 1.05B | 1.32B | 1.63B | 2.11B | 2.53B | 2.98B | 3.6B | 3.46B | 3.16B |
| Common Stock | 875K | 482K | 489K | 498K | 505K | 509K | 513K | 511K | 492K |
| Retained Earnings | 288.66M | 42.1M | 280.33M | 625.41M | 980.75M | 1.43B | 1.89B | 1.81B | 1.39B |
| Treasury Stock | -1.66B | -55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -144.73M | -172.7M | -178.02M | -138.87M | -164.74M | -262.06M | -196.43M | -317.35M | -171.78M |
| Minority Interest | 18.94M | 20.97M | 31.89M | 29.07M | 57.17M | 47.21M | 62.12M | 46.58M | 46.56M |
CRL Cash Flow Statement
Charles River Laboratories International, Inc. (CRL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 316.26M | 441.14M | 480.94M | 546.58M | 760.8M | 619.64M | 683.9M | 734.58M | 737.65M |
| Operating CF Margin % | 17.03% | 19.47% | 18.35% | 18.69% | 21.49% | 15.58% | 16.56% | 18.14% | 18.37% |
| Operating CF Growth % | 6.02% | 39.48% | 9.02% | 13.65% | 39.19% | -18.55% | 10.37% | 7.41% | 0.42% |
| Net Income | 125.59M | 227.22M | 254.06M | 365.31M | 398.84M | 492.61M | 480.37M | 25.29M | -142.16M |
| Depreciation & Amortization | 131.16M | 161.78M | 198.09M | 234.92M | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| Stock-Based Compensation | 44M | 47.35M | 57.27M | 56.34M | 71.47M | 73.62M | 72.05M | 69.89M | 71.08M |
| Deferred Taxes | 28.25M | -9.7M | -21.89M | -133K | -24.01M | -35.88M | -50.9M | -67.43M | -75.29M |
| Other Non-Cash Items | -18.68M | -315K | -12.78M | -83.59M | 6.01M | -62.02M | -29.36M | 375.41M | 466.63M |
| Working Capital Changes | 5.94M | 14.81M | 6.18M | -26.27M | 42.94M | -152.55M | -102.38M | -30.33M | 14.08M |
| Change in Receivables | -48.28M | -21.2M | -8.32M | -85.63M | -26.63M | -150.57M | -33.43M | 21.61M | 35.74M |
| Change in Inventory | -17.84M | -13.34M | -21.4M | -18.38M | -25.16M | -78.52M | -62.3M | 16.8M | -48.78M |
| Change in Payables | 34K | -12.73M | 29.77M | 748K | 44.9M | -2.65M | -20.43M | -14.27M | 2.87M |
| Cash from Investing | -72.59M | -955M | -681.5M | -601.54M | -1.44B | -607.92M | -563.15M | -245.09M | -209.32M |
| Capital Expenditures | -82.43M | -140.05M | -140.51M | -166.56M | -228.77M | -324.73M | -318.53M | -232.97M | -219.15M |
| CapEx % of Revenue | 4.44% | 6.18% | 5.36% | 5.7% | 6.46% | 8.17% | 7.71% | 5.75% | 5.46% |
| Acquisitions | 47.45M | -824.87M | -515.7M | -418.63M | -1.17B | -120.12M | -194.78M | -5.48M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -516K | -805K | -3.89M | -1.06M | 264K | -9.35M | -2.29M | 4.55M | 20.8M |
| Cash from Financing | -208.48M | 558.06M | 231.94M | 47.25M | 672.6M | -42.4M | -85.52M | -550.93M | -536.73M |
| Debt Issued (Net) | -135.58M | 554.02M | 233.87M | 30.59M | 669.98M | 19.79M | -75.32M | -412.19M | -121.78M |
| Equity Issued (Net) | -106.91M | -13.85M | -18.09M | -23.98M | -40.71M | -38.65M | -24.16M | -119.17M | -359.96M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -106.91M | -13.85M | -18.09M | -23.98M | -40.71M | -38.65M | -24.16M | -119.17M | -360.67M |
| Other Financing | 34.01M | 17.88M | 16.15M | 40.64M | 43.32M | -23.54M | 13.96M | -19.56M | -54.98M |
| Net Change in Cash | 46.44M▲ 0% | 30.99M▼ 33.3% | 42.73M▲ 37.9% | -6.93M▼ 116.2% | 13.2M▲ 290.5% | -5.1M▼ 138.7% | 43.27M▲ 948.4% | -78.91M▼ 282.4% | 10.43M▲ 113.2% |
| Free Cash Flow | 233.83M▲ 0% | 301.09M▲ 28.8% | 340.42M▲ 13.1% | 380.01M▲ 11.6% | 532.03M▲ 40.0% | 294.91M▼ 44.6% | 365.37M▲ 23.9% | 501.61M▲ 37.3% | 518.49M▲ 3.4% |
| FCF Margin % | 12.59% | 13.29% | 12.99% | 13% | 15.03% | 7.42% | 8.85% | 12.39% | 12.91% |
| FCF Growth % | -3.78% | 28.76% | 13.06% | 11.63% | 40% | -44.57% | 23.89% | 37.29% | 3.37% |
| FCF per Share | 4.81 | 6.14 | 6.85 | 7.51 | 10.35 | 5.75 | 7.10 | 9.72 | 10.46 |
| FCF Conversion (FCF/Net Income) | 2.56x | 1.95x | 1.91x | 1.50x | 1.95x | 1.27x | 1.44x | 71.34x | -5.11x |
| Interest Paid | 27.42M | 47.54M | 67.81M | 72.46M | 70.78M | 100.75M | 132.1M | 123.45M | 0 |
| Taxes Paid | 60.38M | 67.6M | 54.06M | 60.06M | 75.44M | 75.91M | 90.37M | 126.06M | 0 |
CRL Key Ratios
Charles River Laboratories International, Inc. (CRL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 19.11% | 12.86% | 18.85% | 16.77% | 19.12% | 16.51% | 17.32% | 14.21% | 0.29% | -4.3% |
| Return on Invested Capital (ROIC) | 10.23% | 10.77% | 10.17% | 8.37% | 8.62% | 9.19% | 8.54% | 7.51% | 2.73% | 6.3% |
| Gross Margin | 38.3% | 37.73% | 37.07% | 36.56% | 36.72% | 37.7% | 36.79% | 36.39% | 32.88% | 30.52% |
| Net Margin | 9.2% | 6.64% | 9.99% | 9.61% | 12.46% | 11.04% | 12.23% | 11.49% | 0.25% | -3.59% |
| Debt / Equity | 1.45x | 1.08x | 1.27x | 1.22x | 1.01x | 1.24x | 1.02x | 0.84x | 0.78x | 0.95x |
| Interest Coverage | 9.05x | 10.97x | 5.42x | 5.99x | 6.17x | 7.50x | 11.51x | 5.25x | 1.74x | 4.74x |
| FCF Conversion | 1.93x | 2.56x | 1.95x | 1.91x | 1.50x | 1.95x | 1.27x | 1.44x | 71.34x | -5.11x |
| Revenue Growth | 23.34% | 10.48% | 21.99% | 15.67% | 11.55% | 21.08% | 12.31% | 3.86% | -1.92% | -0.85% |
CRL SEC Filings & Documents
Charles River Laboratories International, Inc. (CRL) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRL Frequently Asked Questions
Charles River Laboratories International, Inc. (CRL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Charles River Laboratories International, Inc. (CRL) reported $4.02B in revenue for fiscal year 2025. This represents a 1977% increase from $193.3M in 1998.
Charles River Laboratories International, Inc. (CRL) saw revenue decline by 0.9% over the past year.
Charles River Laboratories International, Inc. (CRL) reported a net loss of $144.3M for fiscal year 2025.
Dividend & Returns
Charles River Laboratories International, Inc. (CRL) has a return on equity (ROE) of -4.3%. Negative ROE indicates the company is unprofitable.
Charles River Laboratories International, Inc. (CRL) generated $518.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CRL
Charles River Laboratories International, Inc. (CRL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates